Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the
Vaccine Discovery & Development Conference in Brussels, Belgium in November
October 22, 2009
Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
July 24, 2009
Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
July 17, 2009
May 15, 2009
April 20, 2009
Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
March 1, 2009
Vaccinogen Announces Addition of David Hatt to its Board of Directors
November 14, 2008
November 13, 2008
OncoVAX, Other Vaccines Provide Hope for Colorectal Cancer Treatment, Prevention
June 4, 2008
Thomson Reuters' Pharma Matters highlights Vaccinogen’s OncoVAX® as “One to Watch”
May 7, 2008
February 27, 2008
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
February 11, 2008
Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
November 10, 2007
Vaccinogen Announces the Successful Acquisition of Key Management and Staff
November 4, 2007
Vaccinogen Announces Successful Acquisition of cGMP Manufacturing Facility
November 3, 2007
Vaccinogen Announces Completion of its Initial Capitalization Plan
October 1, 2007
Vaccinogen Announces Formation of Company
July 19, 2006
FDA Grants Special Protocol Assessment
July, 2006
FDA Grants Intracel “Fast Track ” Designation for the Development of Its Colon Cancer Vaccine
Frederick, MD, USA – July 17, 2009 – Vaccinogen, Inc. announces that Michael G. Hanna, Jr., Ph.D. has agreed to “Chair” the first day of the Vaccine Discovery & Development Conference in Brussels, Belgium on November 17-18, 2009. The Chairman’s topic will be on the history of cancer vaccine’s success and failures. Dr. Hanna is also scheduled to make a presentation on the potential of the adaptive immune system for anti-cancer immunotherapy. Vaccines Europe is Europe’s leading event for prophylactic and therapeutic vaccines focusing on opportunities, innovation and scientific developments.
About Dr. Hanna
Dr. Hanna is the founder of Vaccinogen, Inc., the discoverer and developer of OncoVAX®, and a pioneer in
the field of cancer vaccines. He also developed and obtained FDA approval for TICE BCG for treatment of
Carcinoma in Situ ("CIS") bladder cancer. This led to worldwide registration in 1991. It remains the standard
of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Dr. Hanna received a
doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over
250 publications to his credit, has 10 patents in immunotherapy and has been the recipient of numerous
honors, and served on many editorial boards.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen’s scientists prepare a vaccine from the patient’s own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth “booster” is administered six months later. OncoVAX® reduces recurrence and deaths by over 50%.
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, antiinflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX® vaccines.
Contact:
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400